1, Luminal A type ER+PR+Her-2-and ki-67 low expression < 14%< strong=""> Usually early stage breast cancer with low risk of recurrence, sensitive to endocrine therapy, insensitive to chemotherapy, better prognosis. Not suitable for aggressive chemotherapy Not suitable for neoadjuvant chemotherapy But the treatment strategy should be integrated with lymph node status and other risk factors. 2, Luminal B type is divided into: (1) ER+PR+Her-2-and ki-67 high expression >= 14% (2) ER+PR+Her-2+ regardless of ki-67 expression level On the basis of endocrine therapy, sometimes must receive chemotherapy and anti-HER2 targeting therapy; sometimes due to high expression of ki-67, chemotherapy is also considered as one of the treatment means. 3. HER-2(+) type refers to those with ER-PR- and Her-2 positivity. This type has poor histological grading, Ki67 proliferation and epidermal growth factor receptor positivity, poor prognosis, basically ineffective endocrine therapy, short disease-free survival and overall survival, but good chemotherapy and targeted therapy. 4.Basal-like type: ER-;PR-;Her-2-. It is equivalent to triple negative breast cancer. This type of breast cancer highly expresses Ck5/6, or CK17, Her-1, the basal epithelial molecular markers, and has poor histological differentiation and is associated with P53 mutation, and has very poor prognosis. It occurs in women under 40 years of age and accounts for 15% of all breast cancers, with a 5-year survival rate of <15%. 5. Normal-like type: high expression of adipose tissue and non-epithelial genes, low expression of luminal epithelial genes.